[go: up one dir, main page]

WO2008142623A3 - Tumor necrosis factor - alpha inhibitors - Google Patents

Tumor necrosis factor - alpha inhibitors Download PDF

Info

Publication number
WO2008142623A3
WO2008142623A3 PCT/IB2008/051932 IB2008051932W WO2008142623A3 WO 2008142623 A3 WO2008142623 A3 WO 2008142623A3 IB 2008051932 W IB2008051932 W IB 2008051932W WO 2008142623 A3 WO2008142623 A3 WO 2008142623A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
necrosis factor
tumor necrosis
pharmaceutically acceptable
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/051932
Other languages
French (fr)
Other versions
WO2008142623A2 (en
Inventor
Sarala Balachandran
Ram Vishwakarma
Venkatrao Kaki
Vitthal Yadav
Siddheshwar Chauthe
Somesh Sharma
Sapna Parikh
Firuza Kharas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Life Sciences Ltd
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of WO2008142623A2 publication Critical patent/WO2008142623A2/en
Anticipated expiration legal-status Critical
Publication of WO2008142623A3 publication Critical patent/WO2008142623A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to small molecules that inhibit Tumor Necrosis Factor- alpha (TNF-α), for example, by interaction with TNF-α protein or its receptor, thereby lowering the overall TNF-α activity, and that are represented by formula (1) or a stereoisomer thereof, tautomer thereof, or mixture thereof in any ratio; a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable polymorph thereof; wherein: A1, A2, X1, X2, n, R1, R2, R3 and R4 are as defined in the specification. The present invention also relates to processes for the preparation of these small molecules and to pharmaceutical compositions containing them. The present invention further relates to a method of treatment of disorders characterized by increased TNF- α activity, such as inflammation.
PCT/IB2008/051932 2007-05-17 2008-05-16 Tumor necrosis factor - alpha inhibitors Ceased WO2008142623A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93054807P 2007-05-17 2007-05-17
US60/930,548 2007-05-17

Publications (2)

Publication Number Publication Date
WO2008142623A2 WO2008142623A2 (en) 2008-11-27
WO2008142623A3 true WO2008142623A3 (en) 2009-12-30

Family

ID=40032246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/051932 Ceased WO2008142623A2 (en) 2007-05-17 2008-05-16 Tumor necrosis factor - alpha inhibitors

Country Status (1)

Country Link
WO (1) WO2008142623A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
ES2734567T3 (en) * 2012-06-08 2019-12-10 Univ Pittsburgh Commonwealth Sys Higher Education FBXO3 inhibitors
WO2015089087A1 (en) 2013-12-09 2015-06-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for treating respiratory injury or disease
SG11201810861PA (en) * 2014-12-10 2019-01-30 Univ Pittsburgh Commonwealth Sys Higher Education Compositions and methods for treating diseases and conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059959A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US20030013708A1 (en) * 2001-01-16 2003-01-16 Edward Pierson Therapeutic heterocyclic compounds
WO2007004958A1 (en) * 2005-07-04 2007-01-11 Astrazeneca Ab Pyridopyrimidine derivatives as pde4 inhibitors for the treatment of inflammatory and' immune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059959A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US20030013708A1 (en) * 2001-01-16 2003-01-16 Edward Pierson Therapeutic heterocyclic compounds
WO2007004958A1 (en) * 2005-07-04 2007-01-11 Astrazeneca Ab Pyridopyrimidine derivatives as pde4 inhibitors for the treatment of inflammatory and' immune diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM 4 March 2009 (2009-03-04), retrieved from http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pcsubstanceBDbFrom=pcsubstance&Cmd=Link& LinkName=pcsubstance_pcsubstance&LinkReadableName=Similar20Substances8ldsFromRes ult=56442818&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pcsubstance.Pcsubstan Results Panel.Pcsubstan_RVDocSum Database accession no. 25118614. *
DATABASE PUBCHEM. [online] 4 March 2009 (2009-03-04), retrieved from http://www.ncbi.nim.nih.gov/sites/entrez?Db=pcsubstance&DbFrom=pcsubstance&Cmd=Link &LinkName=pcsubstance_pcsubstance&LinkReadableName=Result=56442816[SID &ordinalpos=1&itool=EntrezSystem2.PEntrez.Pcsubstance.Pcsubstance_ResuItsPaneLPcsubs tance_RVDocSum Database accession no. 25118610. *
DATABASE PUBCHEM. 4 March 2009 (2009-03-04), retrieved from http://www.nGbi.nlm.nih.gov/sites/entrez?Db=pcsubstance&DbFrom=pcsubstance&Cmd=Link &LinkName=pcsubstance_csubstance&LinkReadableName=Result=44924038[SID]&ordinalp os=1&itool=EntrezSystem2.PEntrez.Pcsubstance.Pcsubstance ResuItsPanel.Pcsubstan_R VDocSum Database accession no. 9825905. *
HE ET AL.: "Small molecule inhibitors of TNF-alpha.", SCIENCE, vol. 310, November 2005 (2005-11-01), pages 1022 - 1025 *

Also Published As

Publication number Publication date
WO2008142623A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2009106980A3 (en) Indazole derivatives
WO2008061109A3 (en) Indazole derivatives useful as melanin concentrating receptor ligands
NO20084652L (en) Deazapurins useful as inhibitors of januskinases
MX2009004699A (en) Pyridinone compounds.
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2009155527A3 (en) Phosphatidylinositol 3 kinase inhibitors
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
WO2005077344A3 (en) Hydantoin derivatives as inhibitors of cellular necrosis
WO2013049726A3 (en) Processes for making compounds useful as inhibitors of atr kinase
WO2006086488A3 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2010044543A3 (en) Heterocyclic compound as protein kinase inhibitor
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2008119825A3 (en) Imidazolidine carboxamide derivatives as p2x7 modulators
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
WO2007058832A3 (en) Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2008010061A3 (en) 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751223

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08751223

Country of ref document: EP

Kind code of ref document: A2